In a UK first, hospitals in Manchester are using Elecsys GAAD, a pioneering diagnostic test, to detect hepatocellular carcinoma (HCC)—the most common form of liver cancer—at earlier, more curable stages.
The test, developed by Roche Diagnostics, combines blood biomarkers with patient age and gender, enhancing the accuracy of early HCC detection when used alongside standard screening. Since December 2023, the test has been implemented across Manchester University NHS Foundation Trust (MFT) hospitals, which serve a large population with liver disease risk.
Over 600 cirrhosis patients have been screened so far, with four early-stage HCC cases detected that would have otherwise gone unnoticed, offering new hope for curative treatment.
Follow MEDWIRE.AI for early cancer detection innovations.
